IP Library Granted Patent US 8,444,589
Granted Patent B2
US 8,444,589 · App. 13/157,221 · Granted May 21, 2013

Ocular implant with fluid outflow pathways having microporous membranes

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,444,589
App. No.
13/157,221
Granted
May 21, 2013
Kind
B2
Abstract

Disclosed are devices, methods and systems for treatment of eye disease such as glaucoma. Implants are described herein that enhance aqueous flow through the normal outflow system of the eye with minimal to no complications. The implant can include reversibly deformable portions that have a plurality of openings layered, covered or otherwise spanned by an elastomeric film or membrane having micropores. The micropores allow for fluid flow out of the implant while inhibit cellular infiltration and blockage of the openings.

Claims (21)

1. An ocular implant, comprising:

an elongate member comprising:

a flow pathway;

at least one inflow port communicating with the flow pathway;

a plurality of outflow openings communicating with the flow pathway;

a braided structure having a plurality of interwoven struts and openings formed between the interwoven struts, wherein the braided structure is configured to form a first diameter for insertion through a self-sealing incision in the cornea of an eye and further configured to expand from the first diameter to a second diameter upon implantation in the eye; and

an elastomeric membrane spanning between at least one of the openings formed by the interwoven struts, wherein the elastomeric membrane is configured to form a first shape when the braided structure forms the first diameter and form a second shape when the braided structure expands to the second diameter,

wherein the elastomeric membrane has a plurality of pores in fluid communication with the flow pathway; and

wherein the elongate member is adapted to be positioned in the eye such that the at least one inflow port communicates with the anterior chamber and the at least one of the openings communicate with the suprachoroidal space.

2. The implant of claim 1 , wherein the braided structure is adapted to transition between a first shape when in tension and a second shape upon release of tension.

3. The implant of claim 1 , wherein the elastomeric membrane spanning the outflow openings additionally surrounds each of the interwoven struts.

4. The implant of claim 3 , wherein the elastomeric membrane surrounding each of the interwoven struts expands and contracts upon movement of the interwoven struts.

5. The implant of claim 1 , wherein the elastomeric membrane comprises a material selected from the group comprising polyurethane, silicone, Lycra, and Hytrel.

6. The implant of claim 1 , wherein each of the pores are sized to achieve aqueous fluid flow through the outflow openings and substantially prevent passage of material into the outflow openings.

7. The implant of claim 1 , wherein each of the pores have a diameter that is less than 1 micron.

8. The implant of claim 7 , wherein each of the pores have a diameter between about 0.1 microns to 0.8 microns.

9. The implant of claim 1 , wherein the elastomeric membrane has a pore density between about 1 pore per square micron to 10 pores per square micron.

10. The implant of claim 1 , further comprising a second membrane coating the elastomeric membrane.

11. The implant of claim 10 , wherein the second membrane comprises Hydrogel.

12. The implant of claim 10 , wherein the second membrane comprises fibers spanning the pores.

13. The implant of claim 10 , wherein the second membrane spans at least a portion of each of the plurality of pores in the elastomeric membrane.

Assignments (3)
CONFIRMATORY DEED OF ASSIGNMENT EFFECTIVE APRIL 8, 2019 Recorded Dec 10, 2019
From: NOVARTIS AG
To: ALCON INC.
Reel/Frame 051454/0788 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 13, 2016
From: TRANSCEND MEDICAL, INC.
To: NOVARTIS AG
Reel/Frame 038967/0487 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 7, 2011
From: SILVESTRINI, THOMAS A.
To: TRANSCEND MEDICAL, INC.
Reel/Frame 027183/0454 →